• Pachamuthu Balakrishnan, Hussain Syed Iqbal, Saravanan Shanmugham, Janardhanan Mohanakrishnan, Sunil S Solomon, Kenneth H Mayer, and Suniti Solomon.
• YRG Centre for AIDS Research & Education, Voluntary Health Services, Taramani, Chennai, India. bala@yrgcare.org
• Indian J Med Res. 2011 Dec 1; 134 (6): 823834823-34.

AbstractUse of a combination of CD4 counts and HIV viral load testing in the management of antiretroviral therapy (ART) provides higher prognostic estimation of the risk of disease progression than does the use of either test alone. The standard methods to monitor HIV infection are flow cytometry based for CD4+ T cell count and molecular assays to quantify plasma viral load of HIV. Commercial assays have been routinely used in developed countries to monitor ART. However, these assays require expensive equipment and reagents, well trained operators, and established laboratory infrastructure. These requirements restrict their use in resource-limited settings where people are most afflicted with the HIV-1 epidemic. With the advent of low-cost and/or low-tech alternatives, the possibility of implementing CD4 count and viral load testing in the management of ART in resource-limited settings is increasing. However, an appropriate validation should have been done before putting them to use for patient testing.

19 keywords...

hide…